MARKET

OKUR

OKUR

OnKure Therapeutics
NASDAQ
3.990
-0.600
-13.07%
After Hours: 4.000 +0.01 +0.25% 18:57 03/27 EDT
OPEN
3.940
PREV CLOSE
4.590
HIGH
4.000
LOW
3.670
VOLUME
7.06M
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
1.700
MARKET CAP
54.56M
P/E (TTM)
-0.9061
1D
5D
1M
3M
1Y
5Y
1D
OnKure Therapeutics prices $150M oversubscribed private placement
Seeking Alpha · 2d ago
Pre-Market Most Active for Mar 27, 2026 : TQQQ, TSLL, IBIT, OKUR, ETHA, SQQQ, LAR, U, SNAP, NOK, NIO, IONQ
NASDAQ · 2d ago
OnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
TipRanks · 2d ago
OnKure Therapeutics Enters Into Securities Purchase Agreement For Private Placement Raising Gross Proceeds Of ~$150M
Benzinga · 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 2d ago
*OnKure Therapeutics: Liam Ratcliffe Joins Bd of Directors >OKUR
Dow Jones · 2d ago
*OnKure Therapeutics: Expect to File INDs for Each Program in 1H 2027 >OKUR
Dow Jones · 2d ago
ONKURE THERAPEUTICS INC: FINANCING LED BY ACCESS BIOTECHNOLOGY
Reuters · 2d ago
More
About OKUR
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.

Webull offers Onkure Therapeutics Inc stock information, including NASDAQ: OKUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OKUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OKUR stock methods without spending real money on the virtual paper trading platform.